Accepted Manuscript

Title: Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections¹

Authors: Friederike Traunmüller, Michael V. Schintler, Stephan Spendel, Martin Popovic, Oliver Mauric, Erwin Scharnagl, Christian Joukhadar

PII: S0924-8579(10)00130-5
DOI: doi:10.1016/j.ijantimicag.2010.03.007
Reference: ANTAGE 3280

To appear in: *International Journal of Antimicrobial Agents*

Received date: 24-2-2010
Revised date: 3-3-2010
Accepted date: 4-3-2010

Please cite this article as: Traunmüller F, Schintler MV, Spendel S, Popovic M, Mauric O, Scharnagl E, Joukhadar C, Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections¹, *International Journal of Antimicrobial Agents* (2008), doi:10.1016/j.ijantimicag.2010.03.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections [☆]

Friederike Traunmüller ^{a,b,1}, Michael V. Schintler ^{b,1}, Stephan Spendel ^b, Martin Popovic ^{a,c}, Oliver Mauric ^a, Erwin Scharnagl ^b, Christian Joukhadar ^{a,b,d,e,*}

^a *J&P Medical Research Ltd., Vienna, Austria*

^b *Department of Surgery, Division of Plastic Surgery, Medical University of Graz, Austria*

^c *Department of Radiology, Division of Cardiovascular and Interventional Radiology, Medical University of Vienna, Austria*

^d *Beth Israel Deaconess Medical Center, Boston, MA, USA*

^e *Harvard Medical School, Boston, MA, USA*

ARTICLE INFO

Article history:

Received 24 February 2010

Accepted 4 March 2010

Keywords:

Oxazolidinone

Multiple-dose pharmacokinetics

MRSA

Diabetic foot ulcer

Osteomyelitis

* Corresponding author. Present address: J&P Medical Research Ltd., Auhofstrasse
15/8-9, 1130 Vienna, Austria. Tel.: +43 1 8760432 10; fax: +43 1 8760432 33.

E-mail address: christian.joukhadar@jp-medical-research.com (C. Joukhadar).

¹ These authors contributed equally to this work.

☆ Data from this study will be presented as an abstract and poster at the 4th Austrian
Conference on Infectious Diseases, 5–8 May 2010, Saalfelden, Austria.

ABSTRACT

The present study aimed at assessing unbound extracellular concentrations of linezolid in inflamed soft tissue and bone of diabetic patients suffering from severe bacterial foot infections. Linezolid was administered intravenously twice daily at a dosage of 600 mg. At steady-state conditions, the microdialysis technique was utilised to sample serially interstitial space fluid from inflamed subcutaneous adipose tissue and metatarsal bone from 0–8 h post dose in three representative patients. Mean peak concentrations of free linezolid in plasma, healthy subcutis, inflamed subcutis and cancellous bone were 16.6 ± 3.0 , 15.5 ± 2.5 , 15.8 ± 2.8 and 15.1 ± 4.1 mg/L, respectively. The degree of tissue penetration as expressed by the ratio of the area under the concentration–time curve of free linezolid from 0–12 h ($fAUC_{0-12}$) in tissue to the $fAUC_{0-12}$ in plasma was 1.32 ± 0.09 , 1.12 ± 0.22 and 1.09 ± 0.11 for healthy subcutis, inflamed subcutis and bone, respectively. Based on currently available pharmacokinetic/pharmacodynamic targets, we conclude that linezolid administered at 600 mg twice daily may be considered an effective treatment in diabetic patients suffering from bacterial foot infection complicated by osteomyelitis.

1. Introduction

In patients with diabetes, serious complications such as peripheral neuropathy combined with bacterial foot infections account for a large number of hospital stays and are a major cause of non-traumatic amputations of the lower limb. Appropriate management of these complications often requires intravenous (i.v.) administration of potent antimicrobial agents supported by surgical intervention. However, measures like these require co-ordinated interdisciplinary work between surgeons, clinicians, clinical pharmacologists and microbiologists because of uncertainty regarding resistance rates, rapidly evolving outbreaks of multiresistant bacterial strains following long-term therapy with broad-spectrum antibiotics, and incomplete knowledge of drug tissue penetration. Thus, choosing the right antimicrobial agent is essential in these situations.

Linezolid has demonstrated potent in vitro activity against problematic bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA) and glycopeptide-resistant Gram-positive bacteria [1]. The ability of linezolid to penetrate into the extracellular space fluid of soft tissues is well documented in healthy volunteers and critically ill patients [2,3]. However, the rate and extent of penetration of linezolid into bone tissue is controversial in the medical literature [4–7].

Thus, in the present study we aimed to determine the ability of linezolid to penetrate into bone and the interstitium of inflamed subcutaneous adipose tissue in a small representative cohort of diabetic patients suffering from severe diabetic foot infection (DFI). Recently, the microdialysis technique, which was used in this study, was also employed to assess unbound concentrations of linezolid in cancellous bone tissue of

healthy pigs as well as fosfomycin concentrations in healthy and inflamed tissue of diabetic patients presenting with bacterial foot infections complicated by osteomyelitis [7,8].

2. Subjects and methods

This study was performed at the Division of Plastic Surgery, Department of Surgery, Landeskrankenhaus Universitätsklinikum Graz (State Hospital University Clinic of Graz, Graz, Austria). Analytical work was performed at the laboratory of J&P Medical Research Ltd. (Vienna, Austria).

2.1. Study subjects

Three male patients with type II diabetes [Caucasians aged 60–67 years, body mass index (BMI) 26.3–37.2 kg/m²] presenting with deep-seated bacterial foot infections were included in the study after oral and written informed consent was obtained. The patients required surgical debridement with partial metatarsal bone resection and adjuvant systemic antimicrobial therapy. Exclusion criteria were known allergy to linezolid, renal dysfunction indicated by a creatinine clearance of <40 mL/min as estimated by the Cockcroft–Gault formula, and a history of neutropenia or thrombocytopenia. All patients had received non-invasive conservative treatment for DFI prior to enrolment into the study. During the conduct of the study, co-administration of antimicrobial agents or medications other than the study drug was permitted if medically indicated. All patients received at least six standard i.v. doses of linezolid (Zyvoxid™, 600 mg/300 mL solution for infusion; Pfizer Corp., Vienna, Austria) over ca. 30 min twice daily prior to microdialysis.

2.2. Microdialysis and sampling procedures

Microdialysis was performed as described in detail elsewhere [8]. Venous blood was collected at predefined time points from an indwelling i.v. catheter.

2.3. Chemical analysis and determination of plasma protein binding

Linezolid concentrations in plasma and microdialysates were measured by high-performance liquid chromatography (HPLC) with ultraviolet detection as described previously [9]. The lower limit of quantification was 0.05 mg/L both for plasma and microdialysate.

Individual values of plasma protein binding were determined in duplicate by the ultrafiltration method. In brief, aliquots of plasma samples were ultrafiltered using disposable centrifugal filter devices (Ultrafree-MC, molecular cut-off 5000 Da; Millipore, Bedford, MA) at $7500 \times g$ for 30 min. Filtrates were analysed for free linezolid. The bound fraction was calculated by subtracting the free fraction from unity.

2.4. Pharmacokinetic analysis

Pharmacokinetic calculations were carried out using the commercially available computer software Kinetica version 3.0 (InnaPhase, Philadelphia, PA). For the concentrations at 12 h, the baseline steady-state concentrations were utilised. Areas under the concentration–time curve (AUC) were calculated by use of the linear trapezoidal rule.

3. Results

No adverse events related to the study drug or to the microdialysis procedure were observed. Key pharmacokinetic parameters of linezolid in healthy and inflamed subcutaneous adipose tissue and in metatarsal bone are summarised in Table 1. Pharmacokinetic profiles are depicted in Fig. 1.

The degree of tissue penetration as expressed by the free (*f*) tissue to plasma ratios of the AUC from 0–12 h ($fAUC_{0-12 \text{ tissue}}/fAUC_{0-12 \text{ plasma}}$) was 1.32 ± 0.09 , 1.12 ± 0.22 and 1.09 ± 0.11 for healthy subcutis, inflamed subcutis and bone, respectively. Plasma protein binding of linezolid in the study subjects ranged from 18% to 26%.

4. Discussion

MRSA infections associated with unfavourable outcomes are becoming increasingly problematic in diabetic foot clinics [10]. As moderate-to-severe DFI is frequently linked to osteomyelitis of adjacent bones, the ability of certain antibiotic agents to penetrate bone tissue needs to be taken into consideration when aiming for successful treatment of DFI. However, the vast majority of presently available pharmacokinetic data regarding bone tissues focuses on tissue homogenates, which provide no information on the concentration–time course of the drug at the relevant site of most infections, i.e. the extracellular space fluid [7].

Against this background, we utilised the microdialysis technique to determine the pharmacokinetic profiles of unbound linezolid in inflamed subcutaneous adipose

tissue and metatarsal bone. The key finding was that free linezolid in plasma equilibrates completely with soft tissues and bone within ca. 1 h after the start of infusion (Fig. 1). Tissue:plasma ratios of the $fAUC_{0-12}$ were ca. 1, indicating rapid and complete penetration of linezolid into the interstitial space fluid of investigated tissues. It is noteworthy to mention that for measurements in bone, the microdialysis probe was implanted into vital, macroscopically unaffected bone tissue located in close proximity to surgically resected sequestering bone structures.

In addition, it was shown that inflammation did not affect interstitial concentrations of linezolid in soft tissues (Table 1; Fig. 1). This is in line with another study investigating concentrations of linezolid in perinecrotic wound tissue obtained by biopsy from patients with DFIs. In this study, mean tissue penetration of linezolid was 102% as determined 3 h after an oral dose of 600 mg [11]. On the other hand, in a study by Stein et al. [12], penetration of linezolid into soft tissues was only 18–78% (mean 51%) in diabetic patients. It may be speculated that a reduction in blood flow owing to peripheral vascular disease exerted a major impact on the plasma-to-tissue drug equilibration process [13,14]. Thus, in the present investigation, healthy subcutaneous adipose tissue of a more proximal region of the ipsilateral lower limb was used as reference tissue in order to eliminate potential bias from altered blood flow. We did not find any clinically relevant difference between concentrations of linezolid in healthy reference tissue and inflamed subcutaneous adipose tissue or bone (Table 1; Fig. 1).

The ratio of the $fAUC_{0-24}$ in plasma to the minimum inhibitory concentration (MIC) of the infecting pathogen ($fAUC_{0-24 \text{ plasma}}/\text{MIC}$) was shown to be highly predictive of antimicrobial killing and clinical success. In seriously ill patients, the target value of

$fAUC_{0-24 \text{ plasma}}/MIC$ to achieve clinical cure was determined to be 80–120 [15].

However, predictive pharmacokinetic/pharmacodynamic (PK/PD) targets for tissues are not yet established. In this study, the $fAUC_{0-24}/MIC$ target of ca. 100 was attained for relevant pathogens with MICs < 4 mg/L in plasma and all tissues investigated [1].

In summary, based on PK/PD considerations, we conclude that free concentrations of linezolid are sufficient to cover soft tissue and bone infections with MRSA or other Gram-positive bacteria commonly isolated in diabetic patients with foot infections complicated by osteomyelitis.

Funding

The study was supported by an unrestricted grant from Pfizer Corp. (Vienna, Austria).

Competing interests

J&P Medical Research Ltd. is an independent international research institute basically operating according to the Public–Private Partnership concept. CJ is managing director of J&P Medical Research Ltd. and owns 100% options. CJ is also a consultant for pharmaceutical companies. All other authors declare no competing interests.

Ethical approval

The present study protocol was approved by the Ethics Committee of the Medical University of Graz (Austria).

References

- [1] Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.
Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance
program results for 2008. *Diagn Microbiol Infect Dis* 2009;65:404–13.
- [2] Deghanyar P, Buerger C, Zeitlinger M, Islinger F, Kovar F, Müller M, et al.
Penetration of linezolid into soft tissues of healthy volunteers after single and
multiple doses. *Antimicrob Agents Chemother* 2005;49:2367–71.
- [3] Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of
unbound linezolid in plasma and tissue interstitium of critically ill patients after
multiple dosing using microdialysis. *Antimicrob Agents Chemother* 2006;50:2455–
63.
- [4] Lovering AM, Zhang J, Bannister GC, Lankester BJA, Brown JHM, Narendra G,
et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients
undergoing routine hip replacement. *J Antimicrob Chemother* 2002;50:73–7.
- [5] Kutscha-Lissberg F, Hebler U, Muhr G, Köller M. Linezolid penetration into bone
and joint tissues infected with methicillin-resistant staphylococci. *Antimicrob
Agents Chemother* 2003;47:3964–6.
- [6] Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid
penetration into osteo-articular tissues. *J Antimicrob Chemother* 2002;50:747–50.
- [7] Stolle LB, Plock N, Joukhadar C, Arpi M, Emmertsen KJ, Buerger C, et al.
Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis.
Scand J Infect Dis 2008;40:24–9.
- [8] Schintler MV, Traunmüller F, Metzler J, Kreuzwirt G, Spendel S, Mauric O, et al.
High fosfomycin concentrations in bone and peripheral soft tissue in diabetic

- patients presenting with bacterial foot infection. *J Antimicrob Chemother* 2009;64:574–8.
- [9] Swoboda S, Ober M, Anagnostakos K, Geiss HK, Weigand MA, Hoppe-Tichy T. A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies. *Clin Chem Lab Med* 2007;45:1019–22.
- [10] Dang C, Prasad Y, Bouton A, Jude EB. Methicillin-resistant *Staphylococcus aureus* in the diabetic foot clinic: a worsening problem. *Diabet Med* 2003;20:159–61.
- [11] Majcher-Peszynska J, Haase G, Sass M, Mundkowski R, Pietsch A, Klammt S, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. *Eur J Clin Pharmacol* 2008;64:1093–100.
- [12] Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against methicillin-resistant *Staphylococcus aureus* with reduced vancomycin susceptibility in diabetic patients with foot infections. *J Antimicrob Chemother* 2007;60:819–23.
- [13] Joukhadar C, Klein N, Frossard M, Minar H, Stass H, Lackner E, et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. *Clin Pharmacol Ther* 2001;70:532–9.
- [14] Steiner IM, Langenberger H, Marsik C, Mayer BX, Fischer M, Georgopoulos A, et al. Effect of norepinephrine on cefpirome tissue concentrations in healthy subjects. *J Antimicrob Chemother* 2004;53:506–11.
- [15] Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. *Clin Pharmacokinet* 2003;42:1411–23.

Fig. 1. Pharmacokinetic profiles of linezolid in plasma, soft tissues and metatarsal bone in diabetic foot infection following repetitive intravenous doses of 600 mg (mean $\pm$ standard deviation; $n = 3$).

Accepted Manuscript

Table 1

Main pharmacokinetic indices of linezolid in plasma and target tissues of diabetic foot infections following repetitive intravenous doses of 600 mg [median (range); $n = 3$]

Tissue	$C_{\max}$ (mg/L)	$T_{\max}$ (h)	$T_{1/2\beta}$ (h)	V_{ss} (L)	AUC_{0-24} (mg h/L) ^a	$fAUC_{0-24}/MIC$ ^b
Plasma (total)	22.4 (15.2– 26.6)	0.5	9.3 (7.2– 11.1)	36.9 (30.6– 47.5)	229.4 (198.6– 331.7)	–
Plasma (free)	17.8 (12.5– 19.6)	0.5	9.3 (7.2– 11.1)	–	169.1 (162.7– 263.2)	84.6 (81.4– 131.6)
Subcutis (healthy)	13.9 (13.6– 19.0)	2.5 (2.0– 3.0)	8.8 (7.8– 10.9)	–	245.3 (202.3– 349.8)	122.6 (101.1– 174.9)
Subcutis (inflamed)	17.4 (11.9– 18.3)	2.0 (1.5– 3.0)	9.3 (7.9– 9.5)	–	210.9 (210.7– 212.9)	105.4 (105.4– 106.5)
Metatarsal bone	17.0 (9.3– 18.9)	2.5 (1.5– 2.5)	9.2 (8.1– 12.2)	–	210.4 (165.6– 266.0)	105.2 (82.8– 133.0)

$C_{\max}$, peak concentration; $T_{\max}$, time to $C_{\max}$; $T_{1/2\beta}$, half-life at β -phase; V_{ss} , volume of distribution at steady-state; AUC_{0-x} , area under the concentration–time curve from 0– x h; f , free; MIC, minimum inhibitory concentration.

^a Calculated for twice daily administration ($AUC_{0-12} \times 2$).

^b Example for methicillin-resistant *Staphylococcus aureus* (MRSA) (MIC = 2 mg/L).